Alerta

METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS

Resumen de: WO2026151664A1

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and/or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

INSULIN FRAGMENT TAG AND PHARMACEUTICAL COMPOSITION

Resumen de: US20260201010A1

The present invention addresses the problem of providing a polypeptide tag that is capable of delivering peptides or polypeptides to neurons. The problem is solved by an insulin fragment tag for delivering interested molecules to neurons, the insulin fragment tag comprising a polypeptide including an amino acid sequence that has at least 90% identity with the amino acid sequence of at least one chain selected from an insulin A-chain and an insulin B-chain, and the insulin fragment tag having binding capacity insulin receptors.

GLUCOSE LEVEL INDICATOR MODEL WITH MODIFIED ERROR RATE

Resumen de: US20260198867A1

A system is described herein comprising at least one application running on one or more processors of a server, wherein the at least one application is communicatively coupled with one or more sensor devices and a remote mobile device, the one or more sensor devices configured to monitor real time biometric data of a subject, the one or more sensing devices configured to transmit the real time biometric data to the at least one application, the at least one application configured to extract feature data variables from the real time biometric data, apply a predictive model to the feature data variables to predict glucose levels of the subject over a future period of time, and communicate a signal to the mobile device when predicted glucose levels cross either an upper or lower threshold.

SYSTEM, METHOD, AND COMPUTER READABLE MEDIUM FOR CGM-BASED OGTT REPLACEMENT DIAGNOSIS TEST

Resumen de: US20260204418A1

0000 Embodiments relate to a database management system for efficient physiological diagnosis of a specified physiological disorder. The system includes a physical data store containing glucose measurement data and a representation for a classification of the glucose measurement data. The glucose measurement data is associated with controlled glycemic-response consumption activity, the representation being indication that a glucose measurement trace is associated of a specified physiological disorder or is indicative of the specified physiological disorder, or is a surrogate of an existing metabolic test, e.g. OGTT. A processor receives a new glucose measurement possibly associated with controlled glycemic-response consumption activity, and classifies the newly received glucose measurement trace with the representation based either on a disease- or test-specific classifier or based on a matched similarity metric, and ascribes a clinical recommendation or assessment based on the representation of the classified newly received glucose measurement trace.

METHOD OF INDUCING UMBILICAL CORD MESENCHYMAL STEM CELLS TO DIFFERENTIATE INSULIN-LIKE CELLS AND AN APPLICATION THEREOF

Resumen de: US20260201338A1

A method of inducing umbilical cord mesenchymal stem cells to differentiate insulin-like cells and an application thereof, the invention carries out reasonable culture of purified umbilical cord mesenchymal stem cells by adopting culture medium having different substances, and can efficiently and stably induce them to differentiate into insulin-like cells, and the percentage of insulin-positive cells can reach 80%. The cell preparation prepared after induction of umbilical cord mesenchymal stem cells of the invention can be used for the treatment of clinical diabetic patients with high therapeutic efficacy.

INDUCTIVE CHARGING OF AN INFUSION PUMP

Resumen de: US20260199590A1

A user-wearable patch pump system for delivery of insulin or other medicament can include a patch pump having a reusable drive unit and a replaceable and refillable cartridge. The cartridge can selectively attach to and be detached from the drive unit. The cartridge can initially be inserted onto the drive unit in a first orientation at an angle to the drive unit and then be rotated to align the cartridge with the drive unit and lock the cartridge in place on the drive unit to form the patch pump.

Smart Footwear, Insoles or Other Wearables with Electronically Read Sensing Membrane and Self-Identification of Left/Right Status

Resumen de: US20260198800A1

Wearable smart devices are disclosed that incorporate a unique means of detecting or measuring a substance of interest, for example to detect ammonia in the secreted foot sweat of a diabetic via incorporation of the sensing arrangement in a footwear article or insole. The setup employs the combination of a colour-changing sensing membrane responsive to the substance of interest, an optical sensor appropriately positioned to capture the membrane within its field of view, and an illumination means for illuminating the membrane to enable optical imaging thereof, from which a controller can then detect the colour of the membrane and determine the presence or measurement of the substance of interest. A left/right self-identification circuit is included in each wearable smart device to enable a cooperative pair of such devices, worn on different bilateral appendages, to self-identify their left/right designation to the external device that receives the outputted signals from the wearables.

METHOD OF DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO MONOHORMONAL CELLS

Resumen de: US20260201339A1

0000 Compositions and methods are provided for generation of a population of monohormonal from human pluripotent cells. The method comprises sequentially exposing pluripotent stem cells to medium comprising CHIR99021 and Activin A; medium comprising Activin A; medium comprising FGF7; medium comprising retinoic acid, LDN193189, SANT1; medium comprising retinoic acid, LDN193189, SANT1, EGF and FGF2; and differentiation medium. A majority of cells in the population are monohormonal cells produce insulin, but not glucagon, somatostatin or ghrelin.

ADVANCED CONTINUOUS ANALYTE MONITORING SYSTEM

Resumen de: EP4776527A2

The present invention relates generally to systems and methods for processing, transmitting, and displaying data received from continuous analyte sensor 10, such as a glucose sensor. In some embodiments, the continuous analyte sensor system 8 comprises a sensor electronics module 12 that includes power saving features. One feature includes a low power measurement circuit that can be switched between a measurement mode and a low power mode, in which charging circuitry continues to apply power to electrodes of a sensor during the low power mode. In addition, the sensor electronics module can be switched between in a low power storage mode higher power operational mode via a switch. The switch can include a reed switch or optical switch, for example. A validation routine can also be implemented to ensure an interrupt signal sent from the switch is valid. The continuous analyte sensor 10 can be physically connected to a sensor electronics module 12, which is in direct wireless communication with a plurality of different display devices 14, 16, 18, and/or 20.

LINEAR TIME-VARYING MODEL PREDICTIVE CONTROL OF AN ARTIFICIAL PANCREAS WITH BLOOD GLUCOSE PREDICTORS

Resumen de: WO2025054131A1

A blood glucose monitoring system having an insulin pump operational to administer insulin to the subject, sensors associated with the subject and operational to measure the blood glucose levels of a subject, and a computing device in electronic communication with the insulin pump. The computing device includes computer readable storage mediums having program code embodied therewith. The computing device includes a closed-loop insulin delivery algorithm trained to predict the blood glucose level of the subject. The algorithm includes a data-driven multi-step- ahead blood glucose predictor integrated with a linear time-varying model predictive control law. The computing device includes programming instructions for feeding the subject's blood glucose level into the algorithm, using the algorithm to predict if the blood glucose level of the subject is expected to reach a level representing hypoglycemia or hyperglycemia, and transmitting insulin administration instructions to the insulin pump based on the prediction.

DEVICE FOR COLLECTION OF VOLATILE COMPOUNDS FROM SKIN FOR NON-INVASIVE MEASUREMENT OF BLOOD-GLUCOSE VALUES

Nº publicación: ES3073683T3 14/07/2026

Solicitante:

F HOFFMANN LA ROCHE AG
F. Hoffmann-La Roche AG

Resumen de: WO2021167918A1

A volumetric sampling apparatus for volatile compounds comprises a structure, such as a channel structure that forms a continuous curve between the inlet port and the outlet port. A gas flow induced in the structure urges volatile compounds collected via transdermal diffusion toward the outlet port, where the volatile compounds may be collected and analyzed.